|1.||Collaborative Study Group: 6 articles (10/2015 - 01/2013)|
|2.||Dwyer, Jamie P: 6 articles (10/2015 - 01/2013)|
|3.||Sika, Mohammed: 6 articles (10/2015 - 01/2013)|
|4.||Lewis, Julia B: 5 articles (10/2015 - 01/2013)|
|5.||Umanath, Kausik: 5 articles (10/2015 - 01/2013)|
|6.||Niecestro, Robert: 4 articles (10/2015 - 01/2013)|
|7.||Koury, Mark J: 3 articles (10/2015 - 01/2013)|
|8.||Yokoyama, Keitaro: 3 articles (03/2014 - 01/2012)|
|9.||Hirakata, Hideki: 3 articles (03/2014 - 01/2012)|
|10.||Akiba, Takashi: 3 articles (03/2014 - 01/2012)|
12/07/2015 - "Ferric citrate (Auryxia) for hyperphosphatemia."
05/01/2015 - "Ferric citrate (Auryxia) for the treatment of hyperphosphatemia. "
05/01/2015 - "Ferric citrate (auryxia) for the treatment of hyperphosphatemia."
01/01/2015 - "Although safer and more effective phosphate binders are expected in the future, ferric citrate hydrate will become a new approach for the treatment of hyperphosphatemia."
01/01/2015 - "In 2014, a novel phosphate binder, ferric citrate hydrate (Riona(®)), became available for the treatment of hyperphosphatemia in Japan, the first country to approve this medication. "
|2.||Chronic Kidney Failure (Chronic Renal Failure)
07/01/2002 - "Efficacy of ferric citrate as a phosphate-binding agent in end-stage renal disease."
01/01/2013 - "Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis."
01/01/2014 - "Currently, the potential health care cost savings on a national scale due to the use of ferric citrate in ESRD are undetermined. "
11/01/2014 - "Ferric citrate (Zerenex™, Keryx Biopharmaceuticals, Inc.), a phosphate binder drug candidate, recently completed a Phase III program confirming efficacy and demonstrating safety when used to treat hyperphosphatemia in patients with end-stage renal disease. "
11/01/2014 - "Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data."
|3.||Iron-Deficiency Anemia (Anemia, Iron Deficiency)
05/01/2015 - "A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5."
09/01/2015 - "Ferric citrate is thus a preferred phosphate binder that helps resolve CKD-related mineral bone disease and iron-deficiency anemia. "
01/01/2007 - "Fcy exhibited the same beneficial effect in improving iron deficiency anemia as ferric citrate, being significantly greater than the effect of heme iron. "
01/01/2007 - "We studied the effect of Fcy in male Sprague-Dawley rats with iron-deficiency anemia, which were separated into three different dietary groups (n=5) and supplementing diets as follows: (i) ferric citrate, (ii) heme iron concentrate, and (iii) Fcy (35 mg Fe/kg diet) for three weeks. "
09/01/1978 - "The design and use of iron(III) chelates in the oral treatment of iron-deficiency anemia is discussed in terms of the following criteria: (1) the ability of a chelate to exist as a monomeric species even at physiological pH values, (2) the rate of transfer of iron from the chelate to the iron-transporting protein-apotransferrin, (3) the rate of depolymerization of ferric citrate polymer by the free ligand, and (4) its nontoxicity and ability to regenerate hemoglobin levels in anemic rats. "
01/01/1985 - "Injection of ferric citrate prior to 111In administration resulted in a significant reduction of 111In uptake in the liver, spleen and tumor and increased the amount of activity recovered from the kidney. "
09/01/2013 - "Measurement of fractional blood volume was similar in all tumors (2.6 AU ± 0.5 × 10(-3) for CV1, 2.3 AU ± 0.3 × 10(-3) for CV1-FHC, 2.9 ± 0.3 × 10(-3) for CV1-FHC-ferric citrate). "
04/14/2000 - "However, in those mice, which consumed FO or FO with ferric citrate, treatment with DOX caused significant tumor regression."
08/01/1978 - "Tissue distributions of i.v.-injected Ga-67 citrate and [59Fe] ferric citrate were measured in normal mice and in lymphoid-tumor hosts. "
04/01/2002 - "Efficacy of immunization with ferric citrate receptor FecA from Escherichia coli on induced coliform mastitis."
04/01/2002 - "The effects of immunization with the ferric citrate receptor FecA on antibody responses and on experimentally induced mastitis following intramammary challenge were investigated. "
|4.||Transferrin (beta 2 Transferrin)
|5.||Citric Acid (Citrate)
|8.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Renal Dialysis (Hemodialysis)